SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 206.33+3.6%3:43 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (29963)1/8/2000 3:00:00 PM
From: Torben Noerup Nielsen  Read Replies (1) of 32384
 
Henry,

If the drug has even a reasonable chance of retarding tumor growth, patients will find a doctor who will write the prescription. Moreover, news will spread fast through the breast cancer support groups.

There's also plaque psoriasis to consider. If Targretin happens to be effective there, it's a substantial market since that is a life-long disease.

But we need the trial results. One more positive Targretin trial should be sufficient to cause LGND to become fairly valued in very short order.

Incidentally, I wonder how many doctors might try Targretin on non-refractory CTCL. Reading the case histories Henry posted, current treatments sound like cruel and unusual punishment and with the low *and* manageable toxicity of Targretin, I don't see why it wouldn't be used as a first line treatment in short order. Use small dosages to start with to establish individual tolerances and see how effective it is against the disease. Then ramp up the dosage till you either get results against the disease or run into tolerance problems.

Thanks, Torben
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext